

PATIENT

Groucho Spence

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

9 years

WEIGHT

8.2lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

C. Belan, DVM

HOSPITAL NAME

McKnight 24 Hour
Animal Hospital

REFERRING VET

Dr. Gruffydd

INVOICE

23556

DATE

4/11/22

PRESENTING CLINICAL SIGNS

History: Recheck echo. Sedated with butorphanol.

-Current medications: Pimobendan.

-Pertinent previous echo findings (10/2021 MML): Moderate MR, no LA/LVE, moderate TR, moderate PAH, mild RHE. TR: 3.5, LA: 1.38, LV: 1.4.

ECHOCARDIOGRAM FINDINGS


2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets with mild prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with mild left atrial dilatation. Normal MR velocity. Normal LV diameter with adequate myocardial function. The tricuspid valve appears mildly thickened with septal prolapse and moderate tricuspid regurgitation. Velocity consistent with moderate pulmonary hypertension. Moderate right atrial enlargement. Mild right ventricle enlargement with hypertrophy. The MPA is prominent. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities with laminar flow. No obvious aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No obvious cardiac masses.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)	
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6	
PATIENT	5.5	4.1	1.7	1.5	61	92	0.22	
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)	
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW	
PATIENT	100	0.8	0.9	3.7	1.6	1.5	0.6	
*Normal chamber parameters expressed as a mean value (SD)					3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS					5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>					10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
					15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
					20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
					25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
					30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
					35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
					40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
					50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of mild progression. Moderate mitral regurgitation is similar with a slight increase in left atrial dimension comparatively. The right heart is progressively enlarged however, with worsening pulmonary pressures. The overall pulmonary hypertension remains within the moderate category. No additional issues are identified.



PATIENT

Groucho Spence

Given these findings, Pimobendan should be continued as prescribed. Additionally, if the patient exhibits any clinical signs that are respiratory in origin, Sildenafil is also indicated. No obvious indication for additional medications in a patient without any reported symptoms. Close follow up is advised going forward.

SPECIES

Canine

Continued assessment of progression in the future will help predict long term prognosis, which is guarded at this stage (B2). Omega fatty acid supplementation and mild salt restriction may be of some long-term benefit. Monitor for development of a cough, labored breathing, exercise intolerance or collapse episodes.

BREED

Chihuahua

SEX

Male Neutered

Anesthetic risk is considered mild if needed. Cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, isoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Mild IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

AGE

9 years

PLAN

Continue Pimobendan as prescribed. If any respiratory issues or syncope develop in the future, institute Sildenafil 1-2mg/kg PO q12h.

WEIGHT


8.2lbs

Recommend conservative monitoring with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGES



IMAGING PERFORMED BY

C. Belan, DVM

HOSPITAL NAME

McKnight 24 Hour
Animal Hospital

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

REFERRING VET

Dr. Gruffydd

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

INVOICE

23556

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com

DATE

4/11/22